T

Thor Medical ASA
OSE:TRMED

Watchlist Manager
Thor Medical ASA
OSE:TRMED
Watchlist
Price: 4.19 NOK 1.95% Market Closed
Market Cap: 1.5B NOK

Operating Margin
Thor Medical ASA

-33 300%
Current
-5 550%
Average
-4.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-33 300%
=
Operating Profit
-33.3m
/
Revenue
100k

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
NO
Thor Medical ASA
OSE:TRMED
1.5B NOK
-33 300%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
395.1B USD
33%
US
Amgen Inc
NASDAQ:AMGN
174.1B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
148.5B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.4B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.7B USD
28%
AU
CSL Ltd
ASX:CSL
85.8B AUD
26%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.5B USD
8%
NL
argenx SE
XBRU:ARGX
44.3B EUR
22%
No Stocks Found

Thor Medical ASA
Glance View

Market Cap
1.5B NOK
Industry
Biotechnology

Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The company is headquartered in Oslo, Oslo and currently employs 16 full-time employees. The company went IPO on 2014-07-07. The firm is engaged in the development and commercialization of targeted therapeutics for hematological cancers. Its main product is Betalutin, a CD37-targeting radio-immunoconjugate designed to advance the treatment of non-Hodgkin lymphoma (NHL). Betalutin uses monoclonal antibodies to attack the cancer cells in two ways, first as an immunotherapy and secondly as a targeting agent for a radioactive payload and is a combination of radiation therapy and immunotherapy. The firm is also leveraging its expertise in radionuclides and CD37-targeting antibodies, along with partners, to build a pipeline of biopharmaceuticals for a range of haematological cancers.

TRMED Intrinsic Value
0.64 NOK
Overvaluation 85%
Intrinsic Value
Price
T
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-33 300%
=
Operating Profit
-33.3m
/
Revenue
100k
What is the Operating Margin of Thor Medical ASA?

Based on Thor Medical ASA's most recent financial statements, the company has Operating Margin of -33 300%.

Back to Top